EBITDA for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $5.82B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$5.82B
YoY change
+9.4%
5Y CAGR
+7.2%
Peak year (2021)
$9.67B
Cumulative EBITDA
$46.46B
EBITDA history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
EBITDA history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $5.82B | +9.4% | ||
| 2024 | $5.32B | +13.3% | ||
| 2023 | $4.69B | -10.8% | ||
| 2022 | $5.26B | -45.6% | ||
| 2021 | $9.67B | +135.7% | ||
| 2020 | $4.10B | +53.7% | ||
| 2019 | $2.67B | -2.2% | ||
| 2018 | $2.73B | +21.4% | ||
| 2017 | $2.25B | +56.0% | ||
| 2016 | $1.44B | +9.7% | ||
| 2015 | $1.31B | +51.8% | ||
| 2014 | $865.80M | +8.1% | ||
| 2013 | $801.00M | +61.3% | ||
| 2012 | $496.67M | -391.3% | ||
| 2011 | -$170.53M | +125.4% | ||
| 2010 | -$75.66M | +36.7% | ||
| 2009 | -$55.37M | -9.7% | ||
| 2008 | -$61.32M | -25.3% | ||
| 2007 | -$82.07M | +7.3% | ||
| 2006 | -$76.52M | +12.7% | ||
| 2005 | -$67.90M | -198.1% | ||
| 2004 | $69.24M | -175.7% | ||
| 2003 | -$91.51M | -19.4% | ||
| 2002 | -$113.50M | +42.6% | ||
| 2001 | -$79.61M | +281.7% | ||
| 2000 | -$20.86M | +2.2% | ||
| 1999 | -$20.40M | +114.7% | ||
| 1998 | -$9.50M | +2.2% | ||
| 1997 | -$9.30M | -17.0% | ||
| 1996 | -$11.20M | +558.8% | ||
| 1995 | -$1.70M | -93.2% | ||
| 1994 | -$25.00M | -30.0% | ||
| 1993 | -$35.70M | +119.0% | ||
| 1992 | -$16.30M | +85.2% | ||
| 1991 | -$8.80M | +193.3% | ||
| 1990 | -$3.00M | — |
EBITDA values are taken from Regeneron Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Regeneron Pharmaceuticals (REGN) EBITDA is $5.82B – grew 9.4% year-over-year.
Across 2020–2025 (5 years), Regeneron Pharmaceuticals EBITDA produced a CAGR of +7.2% – sustaining 2 straight years of year-over-year growth.
Regeneron Pharmaceuticals EBITDA plunged from $9.67B in 2021 to $5.82B in 2025, a 39.8% drawdown.
$9.67B stands as the all-time-high annual EBITDA, posted in 2021, against a low of -$170.53M during 2011.
Regeneron Pharmaceuticals (REGN) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Regeneron Pharmaceuticals EBITDA by Year
Regeneron Pharmaceuticals EBITDA 2025: $5.82B
Regeneron Pharmaceuticals EBITDA in 2025 was $5.82B, grew 9.4% from 2024.
Regeneron Pharmaceuticals EBITDA 2024: $5.32B
Regeneron Pharmaceuticals EBITDA in 2024 was $5.32B, grew 13.3% from 2023.
Regeneron Pharmaceuticals EBITDA 2023: $4.69B
Regeneron Pharmaceuticals EBITDA in 2023 was $4.69B, declined 10.8% below 2022.
Regeneron Pharmaceuticals EBITDA 2022: $5.26B
Regeneron Pharmaceuticals EBITDA in 2022 was $5.26B, plunged 45.6% below 2021.
Regeneron Pharmaceuticals EBITDA 2021: $9.67B
Regeneron Pharmaceuticals EBITDA in 2021 was $9.67B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — EBITDA
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's EBITDA?
- Latest reported EBITDA for Regeneron Pharmaceuticals (REGN) is $5.82B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals EBITDA changed year-over-year?
- Regeneron Pharmaceuticals (REGN) EBITDA changed +9.4% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals EBITDA?
- Regeneron Pharmaceuticals (REGN) EBITDA compound annual growth rate is +7.2% over the most recent 5 years available.
When did Regeneron Pharmaceuticals EBITDA hit its highest annual value?
- Regeneron Pharmaceuticals EBITDA reached its highest annual value of $9.67B in 2021.
What was Regeneron Pharmaceuticals EBITDA in 2024?
- Regeneron Pharmaceuticals (REGN) EBITDA in 2024 was $5.32B.
What was Regeneron Pharmaceuticals EBITDA in 2025?
- Regeneron Pharmaceuticals (REGN) EBITDA in 2025 was $5.82B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.